Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET
Company Participants
Kirk Huntsman - Chariman & CEO
Brad Amman - CFO
Conference Call Participants
Scott Henry - Alliance Global Partners
Lucas Ward - Ascendiant Capital Markets.
Operator
Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode. A question-and-answer session will follow management’s remarks. This conference call is being recorded, and a replay of today’s call will be available on the Investor Relations section of Vivos’ website and will remain posted there for the next 30 days.
I will now hand the call over to Brad Amman, Chief Financial Officer for instructions and the reading of the Safe Harbor statement. Please go ahead.
Brad Amman
Thank you, Lovely. Hello, everyone, and welcome to our third quarter 2024 conference call. A copy of the earnings press release is available on the Investor Relations section of our website at, www.vivos.com/investor-relations.
On today’s call are Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer; and me, Brad Amman, Chief Financial Officer. Today, we’ll review the highlights and financial results for the third quarter 2024 as well as more recent development and Vivos’ plan for the rest of 2024. Following these formal remarks, we will be happy to take questions.
I would also like to remind everyone that today’s call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events.
Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant risks, uncertainties and contingencies, many of which are beyond the company’s control.
Actual results, including without limitation, the results of Vivos’ growth strategies, operational plans, including sales, marketing, distribution, product acquisition, integration, research and development, regulatory initiatives, cost savings plan and plans to generate revenue, as well as future potential results of operations or operating metrics such as the potential for Vivos to achieve future positive cash flow or profitability and other matters to be addressed by Vivos’ management in this conference call may differ materially and adversely from those expressed or implied by such forward-looking statements.